Paper39697210
The current socioeconomic and regulatory landscape of immune effector cell therapies.
Sainatham C and 8 others. Front Med (Lausanne), 2024. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. The current socioeconomic and regulatory landscape of immune effector cell therapies. Papers, record 39697210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39697210
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References184
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32527933 | 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32527933 | PubMed |
| 2 | 35442451 | Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. | JAMA Netw Open | 2022 | https://conductscience.org/library/papers/35442451 | PubMed |
| 3 | 38763416 | TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/38763416 | PubMed |
| 4 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 5 | 31031762 | Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. | Front Immunol | 2019 | https://conductscience.org/library/papers/31031762 | PubMed |
| 6 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 7 | 37047272 | CAR T Cell Therapy: A Versatile Living Drug. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047272 | PubMed |
| 8 | 22700725 | Economics of hematopoietic cell transplantation. | Blood | 2012 | https://conductscience.org/library/papers/22700725 | PubMed |
| 9 | 29491696 | The 21st Century Cures Act: FDA Implementation One Year Later: Some Action, Some Results, Some Questions. | P T | 2018 | https://conductscience.org/library/papers/29491696 | PubMed |
| 10 | 16728277 | Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. | Exp Hematol | 2006 | https://conductscience.org/library/papers/16728277 | PubMed |
| 11 | 35523472 | Bench at Bedside Models Facilitate CAR-T Cell Supply Chain. | Transplant Cell Ther | 2022 | https://conductscience.org/library/papers/35523472 | PubMed |
| 12 | 28366766 | Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. | Mol Ther | 2017 | https://conductscience.org/library/papers/28366766 | PubMed |
| 13 | 28061985 | Multiple myeloma epidemiology and survival: A unique malignancy. | Semin Oncol | 2016 | https://conductscience.org/library/papers/28061985 | PubMed |
| 14 | 34279805 | Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care. | Adv Ther | 2021 | https://conductscience.org/library/papers/34279805 | PubMed |
| 15 | 38077331 | Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations. | Front Immunol | 2023 | https://conductscience.org/library/papers/38077331 | PubMed |
| 16 | 37754534 | Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update. | Curr Oncol | 2023 | https://conductscience.org/library/papers/37754534 | PubMed |
| 17 | 30884772 | Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30884772 | PubMed |
| 18 | 33312759 | Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33312759 | PubMed |
| 19 | 34904798 | Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34904798 | PubMed |
| 20 | 29451276 | Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. | Drugs Today (Barc) | 2017 | https://conductscience.org/library/papers/29451276 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42935367 | An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres. | Med J Aust | 2026 | https://conductscience.org/library/papers/42935367 | PubMed |
| 42812538 | The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment. | Front Mol Med | 2026 | https://conductscience.org/library/papers/42812538 | PubMed |
| 42733623 | A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia. | Blood Lymphat Cancer | 2026 | https://conductscience.org/library/papers/42733623 | PubMed |
| 42512343 | Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512343 | PubMed |
| 42321853 | Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/42321853 | PubMed |
| 42240912 | Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42240912 | PubMed |
| 42098290 | A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42098290 | PubMed |
| 41993194 | CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. | Front Immunol | 2026 | https://conductscience.org/library/papers/41993194 | PubMed |
| 41976395 | Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976395 | PubMed |
| 41958651 | Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/41958651 | PubMed |
| 41928252 | In vivo CAR-T therapy: from molecular design to precision delivery. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41928252 | PubMed |
| 41900826 | The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41900826 | PubMed |
| 41832248 | Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41832248 | PubMed |
| 41718362 | Activated Lymphocyte-Based Immunotherapy Plus Tomotherapy in an Older Patient with Stage III Lung Cancer: A Case Report. | Geriatrics (Basel) | 2026 | https://conductscience.org/library/papers/41718362 | PubMed |
| 41559435 | CAR-engineered cell therapies: current understandings and future perspectives. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41559435 | PubMed |
| 41089193 | Exploring the interactions of integrins and CEACAM6 (Review). | Exp Ther Med | 2025 | https://conductscience.org/library/papers/41089193 | PubMed |
| 41012519 | Formulation of Recombinant Therapeutic Proteins: Technological Innovation, Regulations, and Evolution Towards Buffer-Free Formulations. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41012519 | PubMed |
| 40890617 | Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis. | BMC Nephrol | 2025 | https://conductscience.org/library/papers/40890617 | PubMed |
| 40616240 | Experience and Needs of Immunotherapy for Lung Cancer Patients: A Meta-Synthesis of Qualitative Studies. | Psychooncology | 2025 | https://conductscience.org/library/papers/40616240 | PubMed |
| 40603629 | CAR T cell therapy for children with rheumatic disease: the time is now. | Nat Rev Rheumatol | 2025 | https://conductscience.org/library/papers/40603629 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CARS1 | 833 | PubTator's text mining | https://conductscience.org/library/genes/833 | NCBI Gene |
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
| TRBV20OR9-2 | 6962 | PubTator's text mining | https://conductscience.org/library/genes/6962 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39697210
GET https://conductscience.org/api/papers/v1/39697210/references?page=2